Company name changed to CARUS Bio

Selected for a gene delivery vehicle acceleration R&D project (commissioned institution / Ministry of Science and ICT)

Conducted a technology development project for OMV vaccine quality evaluation (led by Kookmin University / Ministry of Food and Drug Safety)

Healthcare Division: Launched the electrolyte drink 'LivHyd Tomato Water'

Advanced development of in vivo CAR-mRNA technology (in collaboration with Seoul National University)

Healthcare Division: Launched four BioDrone skincare exosome vegan cosmetic products

Participated in K-Beauty Expo Korea 2025

Selected for the investment-linked scale-up technology commercialization BM planning project (Ministry of Trade, Industry and Energy)

Secured investment (Smart & Growth)

Joint research paper with Korea University and Sungkyunkwan University published in an international journal

Filed overseas patent applications for CDV anchor protein engineering (U.S., China)

Joint research paper with Konkuk University published in an international journal

Established the Healthcare Division (registered as a responsible distributor of cosmetics)

Selected for a Korea Drug Development Fund (KDDF) research project

Joint research paper with LONZA published in an international journal

Started sales of umbilical cord-derived stem cells (MCB, WCB)

Launched cell nanoparticle analysis services

Certified as an excellent company for employee invention compensation

Three BioDrone Award research papers published in international journals

Obtained certification as a specialized research business entity (Ministry of Science and ICT)

Won the Bronze Award in the Next-Generation Innovative Drug Delivery Technology category at the 2023 Edison Awards

Certified as an Inno-Biz company (Ministry of SMEs and Startups)

Two projects selected for the 3rd BioDrone Award (Hanyang University)

Selected as a Next-Generation World-Class Product (Ministry of Trade, Industry and Energy)

Signed a BioDrone license-out agreement with Caravan Biologix (U.S.)

Received New Health Technology certification (Ministry of Health and Welfare)

Signed an MOU with the Foundation for Future Medicine

Obtained Intellectual Property Management Certification (Korean Intellectual Property Office)

Selected as a youth-friendly small giant company (Ministry of Employment and Labor)

Received the Minister of Science and ICT Award for contributions to private-sector R&D innovation

Received the KoreaBIO Chairman's Award as an innovative bio growth company

Received the Minister of Health and Welfare Award for contributions to health and medical technology commercialization

Won the Grand Prize in the Venture & Startup Patent Awards

Signed a joint research agreement with NeoCura (China)

Signed a joint research and development agreement with Vect-Horus (France)

Received the IR52 Jang Young-Sil Technology Innovation Award

Selected for the Startup Growth Technology Development Program – Didimdol Project

Certified as an excellent company for employee invention compensation

Signed a joint research and development agreement for mRNA-based gene therapeutics

Selected for the IP-linked R&D strategy support program

Received the Minister's Award for job creation at Bio Entrepreneur Day

Designated as an outstanding corporate research institute

Collaborated with Lonza (Startup Creasphere Program)

Four projects selected for the 1st BioDrone Award

Received New Excellent Technology (NET) certification in healthcare

Obtained Inno-Biz certification

Signed a joint development agreement with Paracelsus Medical University

Obtained a U.S. patent for core BioDrone technology

Certified as an excellent company for employee invention compensation

Secured investment (DB Financial Investment)

Selected DB Financial Investment as lead underwriter for listing

Secured investment (multiple institutions)

Selected as a youth-friendly small giant company

Selected for the Post-TIPS and overseas marketing support program

Designated as a talent-development SME

Selected as a military service designated company through the corporate research institute

Selected for the Advanced Biopharmaceutical R&D Support Program

Secured investment (multiple institutions)

Signed a joint development agreement for a brain tumor therapeutic

Signed an MOU for joint development of a therapeutic for brain diseases

Won the Grand Prize in the Bio category at the Korea Industry Awards

Signed an agreement for joint research and development of new drugs

Selected for a TIPS R&D project

Selected for an investor-linked technology development project

Secured investment

Established a corporate research institute

Selected for the TIPS program

Certified as a venture company

Transferred core patent technology for cell-derived vesicles

Established MDIMUNE Inc.